The right choice depends on the patients needs and health situation
Whether the FDA extends the same designation to retatrutide depends on whether the agency considers the Phase 3 data to represent a substantial improvement over existing therapies
[5] FDA, Warning Letter to Novo Nordisk, Inc
If you delay treatment, or your medication isnt working well enough, and RA inflammation persists, it can cause permanent damage to the joints, explains rheumatologist Angus Worthing, MD, a clinical assistant professor of medicine at Georgetown University Medical Center in Washington, D.C
Newton K, Strasser A, Kayagaki N, Dixit VM
The reconstitution process adds another layer of risk